Stock Analysis
Exact Sciences Corporation (EXAS) Stock Analysis
Exact Sciences Corporation (EXAS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Exact Sciences Corporation (EXAS) currently has an AIQ Score of 46/100, indicating a neutral setup. Risk is the strongest factor at 67/100. Value is the weakest current factor at 37/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
EXAS at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | — |
| AIQ Score | 46/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $20.03B |
| P/E Ratio | -95.37 |
| Forward P/E | — |
| EPS | -$0.45 |
| Revenue TTM | $878.38M |
| Dividend Yield | 0.00% |
| Beta | 1.44 |
| Volume | — |
| 52-week range | — |
| RSI 14 | — |
| 50-Day SMA | $103.02 |
| 200-Day SMA | $74.25 |
| Analyst Price Target | $105.00 |
| Next Earnings | — |
EXAS
OverviewEXAS Stock Analysis Summary
Exact Sciences Corporation (EXAS) currently has an AIQ Score of 46/100, indicating a neutral setup. Risk resilience is the strongest factor at 67/100. Value is the weakest current factor at 37/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, EXAS has AIQ Score of 46/100 with Risk resilience base of 67/100 and fading Value at 37/100. Wait for component alignment before adding exposure.
Risk resilience (67/100) leads while Value (37/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · — stock move · EXAS classified in Medical - Diagnostics & Research.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is EXAS Bullish or Bearish Right Now?
EXAS currently has a neutral overall setup. Risk Resilience is the strongest factor at 67/100, while Value is weakest at 37/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Risk Resilience is supportive at 67/100.
- - Technical consensus has more buy votes than sell votes (37 vs 7).
- - Value is the current constraint at 37/100.
Current Consensus
EXAS's Technical Analysis Consensus is currently Strong Buy, with 37 buy, 1 neutral, and 7 sell votes. EXAS's beta is 1.44, indicating greater market sensitivity than the broad market.
What Changed in EXAS?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the EXAS Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
EXAS Decision Framework
Public evidence layers, setup checks, and risk context for Exact Sciences Corporation.
Exact Sciences Corporation (EXAS) Stock Analysis
Exact Sciences Corporation has an AIQ Score of 46/100 in a Neutral regime. Risk is strongest at 67/100. Beta is 1.44, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | EXAS is in a Neutral AIQ regime with score 46/100. |
| Signal Conflict | The primary conflict is that risk leads at 67/100 while value lags at 37/100. |
| Factor Evidence | Value 37/100 · Quality 44/100 · Risk 67/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 67/100.
Momentum is — and RSI (14) is 74.1.
EXAS is in a Neutral regime at 46/100.
Risk factor is 67/100 with beta 1.44 and annual volatility 43.05%.
Current conflict: risk leads at 67/100 while value lags at 37/100.
EXAS Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
EXAS Fundamentals
EXAS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
EXAS Technical Analysis
EXAS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
EXAS Stock Catalysts
Track EXAS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
EXAS Dividend Analysis
EXAS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
EXAS Financial Data
EXAS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
EXAS Risk Analysis
EXAS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
EXAS Stock News
EXAS stock news, market tone, recent headlines, and catalyst context.
EXAS vs Life Sciences / Tools / CRO Peers
Current peer cohort: EXAS · ILMN · LNTH · MEDP · NTRA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| EXAS Current stock | 46/100 | 37/100 | — | 67/100 | 2.03 | 43.05% | Current |
| ILMN Illumina | 56/100 | 26/100 | 73/100 | 42/100 | 1.82 | 48.56% | EXAS vs ILMN |
| LNTH Lantheus Holdings | 61/100 | 53/100 | 50/100 | 69/100 | 1.86 | 35.16% | EXAS vs LNTH |
| MEDP Medpace Holdings | 53/100 | 30/100 | 44/100 | 60/100 | 0.6 | 44.79% | EXAS vs MEDP |
| NTRA Natera | 52/100 | 34/100 | 63/100 | 63/100 | 1.57 | 48.30% | EXAS vs NTRA |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 4, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 5, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Dec 31, 2025.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching EXAS
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for EXAS
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
EXAS Stock FAQ
What is EXAS stock price today?
Exact Sciences Corporation's current stock price is shown near the top of this overview when the latest quote is available. Use the quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is EXAS bullish or bearish right now?
EXAS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is EXAS's market cap?
EXAS's market cap is $20.03B based on the latest completed market-close snapshot from Sep 5, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is EXAS's current P/E ratio?
EXAS's current P/E ratio is -95.37 based on the latest completed market-close snapshot from Sep 5, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is EXAS's RSI?
EXAS's RSI appears in the technical analysis view when market-close technical data is available. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is EXAS above its 50-day and 200-day moving averages?
EXAS's price versus the 50-day and 200-day moving averages helps describe trend confirmation. The overview and technicals page show this context when those moving-average fields are available.
When is EXAS's next earnings date?
EXAS's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does EXAS pay a dividend?
EXAS's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 5, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.